Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. - Wikidata - wikimedia - TriplyDB

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.

http://www.wikidata.org/entity/Q37346120

about

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa.Mortality and immunological recovery among older adults on antiretroviral therapy at a large urban HIV clinic in Kampala, Uganda.Predictors and outcomes of HIV-infected antiretroviral-naive patients with discordant responses to combination antiretroviral treatment in Asian and Australian populations: results from APHOD HIV RNA suppression and immune restoration: can we do better?Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil.Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV

P2860

Q33933071-DAC968AB-4227-45AA-B44E-FEEB64390851 Q34065045-67E22C56-A4BD-45DB-876B-FF91C595BC4E Q34170487-0D74A90E-8CB3-4A2B-A304-93B87879131E Q34443404-0A6E692B-B34F-4A03-829C-5BDECBF62E52 Q34989582-0D76B58A-862A-41D2-AD1C-3F0A5E70F67E Q35867173-D86A819F-99CA-4FE8-A0F0-C27036DE767E Q36047903-2BB55E8F-D1E8-4945-BF40-1C2782EDF026 Q36082736-C307CC19-8EC1-47AA-B58A-5DDEC39CD4FF Q40779840-564B191D-2B87-40A2-AC7E-822C29CC27DB Q44120477-203EB270-1C2C-492B-8317-1C0CF2A811A0 Q44921660-6E2A7002-3329-4A02-829B-699336917B33 Q58692021-B390AB23-9866-4E70-8F90-DC81EA8BA435

P2860

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression.

http://www.wikidata.org/entity/Q37346120

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Poor baseline immune function ...... e sustained viral suppression.

@en

Poor baseline immune function ...... e sustained viral suppression.

@nl

type

label

Poor baseline immune function ...... e sustained viral suppression.

@en

Poor baseline immune function ...... e sustained viral suppression.

@nl

prefLabel

Poor baseline immune function ...... e sustained viral suppression.

@en

Poor baseline immune function ...... e sustained viral suppression.

@nl

P1433

Q37346120-99D2D8B0-A19C-49EC-9A6C-839934B5180C

P1476

Q37346120-39C69F64-5386-4910-9E62-30D5EF7F3AF5

P2093

Q37346120-0BBCAE14-F2F7-4A09-99E7-53DDFEC61109

Q37346120-0E73B89C-07D1-4687-856B-1DA413629141

Q37346120-10C3F28D-D979-491D-BDD8-D601B763F5DB

Q37346120-7413D832-3566-44F2-98E5-E2E41FBD3FBD

Q37346120-998782D4-563D-495F-BE44-42C64198B23E

Q37346120-A5C71FC7-57F7-44FA-BE81-783874487220

Q37346120-D4B566DC-6C01-4619-9C03-EBDC0F702EE0

P2860

Q37346120-06E7CCB5-15A6-48E8-AD75-F12E84101D45

Q37346120-18BEED70-7F9D-45BC-9353-2F1F5A12F8B0

Q37346120-1D3905CE-27A5-48FE-99EE-8E39353CAA3F

Q37346120-1F885F8C-7103-4205-83CF-4527E687D83F

Q37346120-26175EA8-5B62-4FEA-98BA-C8FBBE9FAA4C

Q37346120-429E34E5-DE9D-458C-8EED-79F897FEC01C

Q37346120-749CE6D5-2FC6-4E06-B81A-E5A6E074DF1B

Q37346120-99D4F1C8-5ECF-48EA-BAD4-E74DD351EA25

Q37346120-AA93D78C-8734-43A9-8CB4-2ED06C0D674B

Q37346120-BDDEB548-1A93-4E63-B283-9368F54DC43E

P304

Q37346120-E1C576E4-F8E0-4F22-8CFA-6932E5E80344

P31

Q37346120-B9F1B427-70B5-4702-832A-00276A47525E

P356

Q37346120-FE4E36E1-DF36-4511-A81C-A26D58FF9479

P407

Q37346120-A1D5A9B4-0F14-46C4-BF63-128569A6054A

P433

Q37346120-66F69AE4-E033-4A8F-86AC-B3CF9198C377

P478

Q37346120-D54DCB4B-6A8D-42C0-BC8B-8EFA6AD7C04B

P50

Q37346120-2A2B5AA1-3D16-441E-A2F2-B15D4CEF35E1

P577

Q37346120-97DE8C31-A1B3-43AC-BFD1-E94D1461D0F4

P698

Q37346120-B90C85C4-C389-43B2-8119-7465EDB66FD4

P921

Q37346120-50CC8E25-D1B4-43A5-9AD3-3B9A8C9D1992

P932

Q37346120-ECEF769E-E84E-4E08-9E93-518BC7BD8283

P356

QAI.0B013E3181945ED4

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Poor baseline immune function ...... e sustained viral suppression.

@en

P2093

Anne Mijch

http://www.w3.org/2001/XMLSchema#string

Australian HIV Observational Database

http://www.w3.org/2001/XMLSchema#string

Brian Mulhall

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

John Chuah

http://www.w3.org/2001/XMLSchema#string

Kathy Petoumenos

http://www.w3.org/2001/XMLSchema#string

Mark Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

CD4+ count-guided interruption of antiretroviral treatment

Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.

P304

307-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3181945ED4

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Kathleen Falster

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19194311

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2743677

http://www.w3.org/2001/XMLSchema#string